Abstract
Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels alone. Clinical and experimental studies suggested that several antiatherosclerotic effects other than lipid lowering also contribute to the observed benefit of statin therapy. These ‘pleiotropic effects’ include improvement of endothelial function, antitrombotic actions, plaque stabilization, reduction of the vascular inflammatory process and anti-oxidation. Statins may also exhibit a wide variety of actions other than antiatherosclerotic effects. Recent observational data documented a potential association between statin use and improvement of fracture risk in osteoporosis. Despite the lack of randomized trials, epidemiological and limited clinical data suggested that statins might retard the pathogenesis of Alzheimers disease. Observational data indicated that the progression of aortic stenosis and valvular calcification might be delayed in statin users. In addition, the deterioration of congestive heart failure may be delayed with statins via anti-inflammatory, vascular endothelial and antiatherosclerotic actions. Furthermore, preliminary clinical studies suggested that, by their immunosuppressive actions statins might reduce the incidence of rejection following organ transplantation. Currently, there is not enough evidence to prescribe therapy for such patients. However, ongoing studies are exploring the role of statin therapy for these new indications. This review will discuss several non-lipid effects of statin therapy currently under investigation.
Keywords: statins, osteoporosis, dementia, aortic stenosis, heart failure, immunomodulation
Current Vascular Pharmacology
Title: Non-Lipid Effects of Statins: Emerging New Indications
Volume: 2 Issue: 4
Author(s): Aylin Yildirir and Haldun Muderrisoglu
Affiliation:
Keywords: statins, osteoporosis, dementia, aortic stenosis, heart failure, immunomodulation
Abstract: Statins are beneficial both in the primary and secondary prevention of atherosclerotic vascular disease and acute events in a broad spectrum of patient subgroups. However, the observed clinical benefit with statin therapy is much greater than expected through the reduction of cholesterol levels alone. Clinical and experimental studies suggested that several antiatherosclerotic effects other than lipid lowering also contribute to the observed benefit of statin therapy. These ‘pleiotropic effects’ include improvement of endothelial function, antitrombotic actions, plaque stabilization, reduction of the vascular inflammatory process and anti-oxidation. Statins may also exhibit a wide variety of actions other than antiatherosclerotic effects. Recent observational data documented a potential association between statin use and improvement of fracture risk in osteoporosis. Despite the lack of randomized trials, epidemiological and limited clinical data suggested that statins might retard the pathogenesis of Alzheimers disease. Observational data indicated that the progression of aortic stenosis and valvular calcification might be delayed in statin users. In addition, the deterioration of congestive heart failure may be delayed with statins via anti-inflammatory, vascular endothelial and antiatherosclerotic actions. Furthermore, preliminary clinical studies suggested that, by their immunosuppressive actions statins might reduce the incidence of rejection following organ transplantation. Currently, there is not enough evidence to prescribe therapy for such patients. However, ongoing studies are exploring the role of statin therapy for these new indications. This review will discuss several non-lipid effects of statin therapy currently under investigation.
Export Options
About this article
Cite this article as:
Yildirir Aylin and Muderrisoglu Haldun, Non-Lipid Effects of Statins: Emerging New Indications, Current Vascular Pharmacology 2004; 2 (4) . https://dx.doi.org/10.2174/1570161043385475
DOI https://dx.doi.org/10.2174/1570161043385475 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Drug Metabolism/Pharmacokinetics and their Relevance Upon Traditional Medicine-based Cardiovascular Drug Research
Current Drug Metabolism Neoangiogenesis Induced by Progenitor Endothelial Cells: Effect of Fucoidan from Marine Algae
Cardiovascular & Hematological Agents in Medicinal Chemistry Fourth Generation of Synthetic Cannabinoid Receptor Agonists: A Review on the Latest Insights
Current Pharmaceutical Design Ethnic and Geographical Differences in Ischaemic Stroke Among Young Adults
Current Vascular Pharmacology Restoration of Cardiomyocyte Function in Streptozotocin-Induced Diabetic Rats after Treatment with Vanadate in a Tea Decoction
Current Pharmaceutical Biotechnology Mitochondrial Biogenesis: Regulation By Endogenous Gases During Inflammation and Organ Stress
Current Pharmaceutical Design Celiac Disease: An Emerging Epidemic
Current Nutrition & Food Science Editorial (Thematic Issue: Measuring Myocyte Oxidative Stress and Targeting Cytokines to Evaluate Inflammatory Response and Cardiac Repair after Myocardial Infarction)
Current Vascular Pharmacology Meet Our Editorial Board Member
Current Cardiology Reviews Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Physiological and Pharmacological Insights into the Role of Ionic Channels in Cardiac Pacemaker Activity
Cardiovascular & Hematological Disorders-Drug Targets The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Annexin A5 Imaging: An Academic Research – Clinical Trials and Theses
Current Molecular Imaging (Discontinued) Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Current Medicinal Chemistry Adiponectin: Merely a Bystander or the Missing Link to Cardiovascular Disease?
Current Topics in Medicinal Chemistry Regulation of G-Protein-Coupled Receptor Signalling by the Scaffolding Proteins Spinophilin/Neurabin 2 and Neurabin 1
Current Chemical Biology Monitoring of the Antiplatelet Drugs Effect in Patients with Coronary Artery Disease: What is the Real Clinical Impact?
Current Vascular Pharmacology Intracellular Signaling of the Aging Suppressor Protein Klotho
Current Molecular Medicine Bone Marrow Mesenchymal Stem Cells: Agents of Immunomodulation and Neuroprotection
Current Stem Cell Research & Therapy